G12V Kras mutations in cervical cancer under virtual microscope of molecular dynamics simulations

Kras mutations and cancers are common and their role in the progression of cancer is well known and elucidated. The present work is searching for the most deleterious mutation of the four found at codon 12 and 13 of Kras in cervical cancers using prediction servers; different servers were used to look into different factors that govern the protein function. The in silico results predicted G12V to be the most devastating; this particular mutation was then subjected to molecular dynamics simulation (MDS) for further analysis. The authors' approach of MDSs helped them to place the native and mutant structure under virtual microscope and observe their dynamics over time. The results generated are enlightening the effect of G12V variation on the dynamics of Kras. The structural variation between the native and mutant Kras over 50 nanoseconds (ns) run varied at every parameter checked and the results are in excellent agreement with the available experimental data.

Cervical cancer; Kras; Mutation; Molecular dynamics simulations.

[1] International Agency for Research on Cancer: “GLOBOCAN 2012: estimated cancer incidence, mortality and prevalence worldwide in 2012”.World Health Organization. Available at: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx.

[2] Wright A.A., Howitt B.E., Myers A.P., Dahlberg S.E., Palescandolo E., Van Hummelen P., et al.: “Oncogenic mutations in cervical cancer: genomic differences between adenocarcinomas and squamous cell carcinomas of the cervix”. Cancer, 2013, 119, 377.

[3] Cao Z.Y.: “China obstetrics and gynecology”. 2nd ed. Beijing: People’s Health Press, 2012.

[4] Shi J.F., Qiao Y.L., Smith J.S., Dondog B., Bao Y.P., Dai D., et al.: “Epidemiology and Prevention of Human Papillomavirus and Cervical Cancer in China and Mongolia”. Vaccine, 2008, 26, M53.

[5] Hakama M., Miller A.B., Day N.E.: “Screening for Cancer of the Uterine Cervix: from the IARC Working Group on Cervical Cancer Screening and the UICC Project Group on the Evaluation of Screening Programmes for Cancer”. WHO (Geneva), IARC (Lyon), and UICC (Geneva) 1986, 1–315. IARC Sci. Publ. 76.

[6] Iida K., Nakayama K., Rahman M.T., Rahman M., Ishikawa M., Katagiri A., et al.: “EGFR gene amplification is related to adverse clinical outcomes in cervical squamous cell carcinoma, making the EGFR pathway a novel therapeutic target”. Br. J. Cancer, 2011, 105, 420.

[7] Janku F., Lee J.J., Tsimberidou A.M., Hong D.S., Naing A., Falchook G. S., et al.: “PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers”. PLoS One, 2011, 6, e22769.

[8] Bertelsen B.I., Steine S.J., Sandvei R., Molven A., Laerum O.D.: “Molecular analysis of the PI3K-AKT pathway in uterine cervical neoplasia: frequent PIK3CA amplification and AKT phosphorylation”. Int. J. Cancer, 2006, 118, 1877.

[9] McIntyre J.B., Wu J., Craighead P.S., Phan T., Köbel M., Lees-Miller S.P., et al.: “PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy”. Gynecol. Oncol., 2013, 128, 409.

[10] Kim T.J., Lee J.W., Song S.Y., Choi J.J., Choi C.H., Kim B.G., et al.: “Increased expression of pAKT is associated with radiation resistance in cervical cancer”. Br. J. Cancer, 2006, 94, 1678.

[11] Pappa K.I., Choleza M., Markaki S., Giannikaki E., Kyroudi A., Vlachos G., et al.: “Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status”. Gynecol. Oncol., 2006, 100, 596.

[12] Kang S., Kim H.S., Seo S.S., Park S.Y., Sidransky D., Dong S.M.: “Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma”. Gynecol. Oncol., 2007, 105, 662.

[13] Jancík S., Drábek J., Radzioch D., Hajdúch M.: “Clinical relevance of KRAS in human cancers.” J. Biomed. Biotechnol., 2010, 2010, 150960. doi: 10.1155/2010/150960. Epub 2010 Jun 7.

[14] Stenzel A., Semczuk A., Rózyńskal K., Jakowicki J., Wojcierowski J.: “Low-risk" and "high-risk" HPV-infection and K-ras gene point mutations in human cervical cancer: a study of 31 cases”. Pathol. Res. Pract., 2001, 197, 597.

[15] García, Dabeiba Adriana, Yazmín Rocío Arias, and Fabio Ancízar Aristizábal. “Detection of genes mutations in the K-ras, H-ras and EGFR in samples of blood plasma and cervical smears for patients with cervical intraepithelial neoplasia III and cervical cancer”. Colombia Médica, 2009, 40, 34.

[16] Mammas I.N., Zafiropoulos A., Koumantakis E., Sifakis S., Spandidos D.A.: “Transcriptional activation of H- and N-ras oncogenes in human cervical cancer”. Gynecol. Oncol., 2004, 92, 941.

[17] Pappa K.I., Choleza M., Markaki S., Giannikaki E., Kyroudi A., Vlachos G., et al.: “Consistent absence of BRAF mutations in cervical and endometrial cancer despite KRAS mutation status”. Gynecol. Oncol., 2006, 100, 596.

[18] Kang S., Kim H.S., Seo S.S., Park S.Y., Sidransky D., Dong S.M.: “Inverse correlation between RASSF1A hypermethylation, KRAS and BRAF mutations in cervical adenocarcinoma”. Gynecol. Oncol., 2007, 105, 662.

[19] Wegman P., Ahlin C., Sorbe B.: “Genetic alterations in the K-Ras gene influence the prognosis in patients with cervical cancer treated by radiotherapy”. Int. J. Gynecol. Cancer, 2011, 21, 86.

[20] MacConaill L.E., Campbell C.D., Kehoe S.M., Bass A.J., Hatton C., Niu L., et al.: “Profiling critical cancer gene mutations in clinical tumor samples”. PLoS One. 2009; 4(11):e7887.

[21] Cibulskis K., Lawrence M.S., Carter S.L., Sivachenko A., Jaffe D., Sougnez C., et al.: “Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples”. Nat. Biotechnol., 2013, 31, 213.

[22] Kumar P., Henikoff S., Ng P.C.: “Predicting the effects of coding nonsynonymous variants on protein function using the SIFT algorithm”. Nat. Protoc., 2009, 4, 1073.

[23] Adzhubei I.A., Schmidt S., Peshkin L., Ramensky V.E., Gerasimova A., Bork P., Kondrashov A.S., Sunyaev S.R.: “A method and server for predicting damaging missense mutations”. Nat. Methods, 2010, 7, 248.

[24] Capriotti E., Calabrese R., Casadio R.: “Predicting the insurgence of human genetic diseases associated to single point protein mutations with support vector machines and evolutionary information”. Bioin-formatics, 2006, 22, 2729.

[25] Li B., Krishnan V.G., Mort M.E., Xin F., Kamati K.K., Cooper D.N., et al.: “Automated inference of molecular mechanisms of disease from amino acid substitutions” Bioinformatics, 2009, 25, 2744.

[26] Ostrem J.M., Peters U., Sos M.L., Wells J.A., Shokat K.M.: “K-Ras (G12C) inhibitors allosterically control GTP affinity and effector interactions”. Nature, 2013, 503, 548.

[27] Hess B., Kutzner C., Van Der Spoel D., Lindahl E.: “GROMACS 4: Algorithms for highly efficient, load-balanced, and scalable molecular simulation”. J. Chem. Theory Comput., 2008, 4, 435.

[28] Accelrys Software Inc.: “Discovery Studio Modeling Environment, Release 3.5”. San Diego: Accelrys Software Inc., 2012.

[29] Berendsen H.J.C., Postma J.P.M., van Gunsteren W.F., Dinola A., Haak J.R.: “Molecular dynamics with coupling to an external bath”. J. Chem. Phys., 1984, 81, 3684.

[30] Cheatham T.E., Miller J.L., Fox T., Darden T.A., Kollman P.A.: “Molecular dynamics simulations on solvated biomolecular systems: the particle mesh ewald method leads to stable trajectories of DNA, RNA, and proteins”. J. Am. Chem. Soc. 1995, 14, 4193.

[31] Humphrey W., Dalke A., Schulten K.: “VMD: visual molecular dynamics”. J. Mol. Graph., 1996, 14, 33.

[32] Turner P. J.: “XMGRACE, Version 5.1.19”. Center for Coastal and Land-Margin Research, Oregon Graduate Institute of Science and Technology, Beaverton, OR, 2005.